Other Species / Isoforms
  NCAPH (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S15-p
LPATMNNsSSETrGH
Upstream
0 8
Regulatory protein:
  • PLK1 (human)
NCAPH (human) LPATMNNsSSETrGH S15-p
NCAPH (mouse) RSETMNSsFLKARGQ S12-p
R20-m1
NNsSSETrGHPHsAs
0 1
NCAPH (human) NNsSSETrGHPHsAs R20-m1
NCAPH (mouse) NSsFLKARGQQDVLs R17
S25-p
ETrGHPHsAssPsEr
Upstream
0 1
Treatment
  • nocodazole
NCAPH (human) ETrGHPHsAssPsEr S25-p
NCAPH (mouse) KARGQQDVLssPLER V22
S27-p
rGHPHsAssPsErVF
0 3
NCAPH (human) rGHPHsAssPsErVF S27-p
NCAPH (mouse) RGQQDVLssPLERVP S24-p
S28-p
GHPHsAssPsErVFP
0 12
NCAPH (human) GHPHsAssPsErVFP S28-p
NCAPH (mouse) GQQDVLssPLERVPP S25-p
S30-p
PHsAssPsErVFPMP
0 2
NCAPH (human) PHsAssPsErVFPMP S30-p
NCAPH (mouse) QDVLssPLERVPPAS L27
R32-m1
sAssPsErVFPMPLP
0 1
NCAPH (human) sAssPsErVFPMPLP R32-m1
NCAPH (mouse) VLssPLERVPPASRP R29
K41-ub
FPMPLPRkAPLNIPG
0 2
NCAPH (human) FPMPLPRkAPLNIPG K41-ub
NCAPH (mouse) PPASRPGKAPLGtPK K38
I46
PRkAPLNIPGtPVLE
0 3
NCAPH (human) PRkAPLNIPGtPVLE I46
NCAPH (mouse) PGKAPLGtPKtPVLE T43-p
T49-p
APLNIPGtPVLEDFP
Upstream
1 44
Kinase, in vitro:
  • CDK2 (human)
Treatment
  • ischemia
NCAPH (human) APLNIPGtPVLEDFP T49-p
NCAPH (mouse) APLGtPKtPVLEDFP T46-p
K62-ub
FPQNDDEkERLQRRR
0 1
NCAPH (human) FPQNDDEkERLQRRR K62-ub
NCAPH (mouse) FPQNDDEKERMQRRR K59
S70-p
ERLQRRRsRVFDLQF
Upstream
Downstream
1 21
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
Treatment
  • nocodazole
NCAPH (human) ERLQRRRsRVFDLQF S70-p
NCAPH (mouse) ERMQRRRSRVFDLQF S67
S78-p
RVFDLQFstDsPRLL
Upstream
0 16
Treatment
  • nocodazole
NCAPH (human) RVFDLQFstDsPRLL S78-p
NCAPH (mouse) RVFDLQFSTDsIHLA S75
T79-p
VFDLQFstDsPRLLA
Upstream
0 4
Treatment
  • nocodazole
NCAPH (human) VFDLQFstDsPRLLA T79-p
NCAPH (mouse) VFDLQFSTDsIHLAs T76
S81-p
DLQFstDsPRLLAsP
Upstream
0 39
Treatment
  • BI_4834
  • nocodazole
NCAPH (human) DLQFstDsPRLLAsP S81-p
NCAPH (mouse) DLQFSTDsIHLAsPN S78-p
S87-p
DsPRLLAsPssRsID
Upstream
0 31
Regulatory protein:
  • OGT (human)
Treatment
  • nocodazole
NCAPH (human) DsPRLLAsPssRsID S87-p
NCAPH (mouse) TDsIHLAsPNRNIDV S83-p
S89-p
PRLLAsPssRsIDIs
0 1
NCAPH (human) PRLLAsPssRsIDIs S89-p
NCAPH (mouse) sIHLAsPNRNIDVST N85
S90-p
RLLAsPssRsIDIsA
0 2
NCAPH (human) RLLAsPssRsIDIsA S90-p
NCAPH (mouse) gap -
S92-p
LAsPssRsIDIsAtI
Upstream
0 11
Regulatory protein:
  • PLK1 (human)
Treatment
  • MLN8054
  • nocodazole
  • ZK-Thiazolidinone
NCAPH (human) LAsPssRsIDIsAtI S92-p
NCAPH (mouse) HLAsPNRNIDVSTTI N87
S96-p
ssRsIDIsAtIPKFT
Upstream
0 4
Treatment
  • nocodazole
NCAPH (human) ssRsIDIsAtIPKFT S96-p
NCAPH (mouse) PNRNIDVSTTISKFT S91
T98-p
RsIDIsAtIPKFTNT
0 1
NCAPH (human) RsIDIsAtIPKFTNT T98-p
NCAPH (mouse) RNIDVSTTISKFTNT T93
Y111-p
NTQITEHySTCIKLS
0 1
NCAPH (human) NTQITEHySTCIKLS Y111-p
NCAPH (mouse) NTQITEHYSTCIKLS Y106
K122-ub
IKLSTENkITTkNAF
0 6
NCAPH (human) IKLSTENkITTkNAF K122-ub
NCAPH (mouse) IKLSSENKITTKNAF K117
K126-ub
TENkITTkNAFGLHL
0 4
NCAPH (human) TENkITTkNAFGLHL K126-ub
NCAPH (mouse) SENKITTKNAFGLHL K121
K142-ub
DFMSEILkQkDtEPT
0 4
NCAPH (human) DFMSEILkQkDtEPT K142-ub
NCAPH (mouse) DFMSEILKQKDAEPT K137
K144-ub
MSEILkQkDtEPTNF
0 1
NCAPH (human) MSEILkQkDtEPTNF K144-ub
NCAPH (mouse) MSEILKQKDAEPTNF K139
T146-p
EILkQkDtEPTNFkV
0 1
NCAPH (human) EILkQkDtEPTNFkV T146-p
NCAPH (mouse) EILKQKDAEPTNFKV A141
K152-ub
DtEPTNFkVAAGtLD
0 6
NCAPH (human) DtEPTNFkVAAGtLD K152-ub
NCAPH (mouse) DAEPTNFKVAAGTLD K147
K152-m1
DtEPTNFkVAAGtLD
0 1
NCAPH (human) DtEPTNFkVAAGtLD K152-m1
NCAPH (mouse) DAEPTNFKVAAGTLD K147
T157-p
NFkVAAGtLDASTkI
0 1
NCAPH (human) NFkVAAGtLDASTkI T157-p
NCAPH (mouse) NFKVAAGTLDASTKI T152
K163-ub
GtLDASTkIyAVRVD
0 1
NCAPH (human) GtLDASTkIyAVRVD K163-ub
NCAPH (mouse) GTLDASTKIYAVRVD K158
Y165-p
LDASTkIyAVRVDAV
0 1
NCAPH (human) LDASTkIyAVRVDAV Y165-p
NCAPH (mouse) LDASTKIYAVRVDAV Y160
Y177-p
DAVHADVyRVLGGLG
0 27
NCAPH (human) DAVHADVyRVLGGLG Y177-p
NCAPH (mouse) DAVHADVYRVLGGLG Y172
K185-ac
RVLGGLGkDAPsLEE
0 1
NCAPH (human) RVLGGLGkDAPsLEE K185-ac
NCAPH (mouse) RVLGGLGKDtPPQGE K180
K185-ub
RVLGGLGkDAPsLEE
0 2
NCAPH (human) RVLGGLGkDAPsLEE K185-ub
NCAPH (mouse) RVLGGLGKDtPPQGE K180
A187
LGGLGkDAPsLEEVE
0 3
NCAPH (human) LGGLGkDAPsLEEVE A187
NCAPH (mouse) LGGLGKDtPPQGEEs T182-p
S189-p
GLGkDAPsLEEVEGH
0 2
NCAPH (human) GLGkDAPsLEEVEGH S189-p
NCAPH (mouse) GLGKDtPPQGEEsHs P184
G195
PsLEEVEGHVAdGsA
0 1
NCAPH (human) PsLEEVEGHVAdGsA G195
NCAPH (mouse) tPPQGEEsHsGDGST S189-p
V197
LEEVEGHVAdGsAtE
0 5
NCAPH (human) LEEVEGHVAdGsAtE V197
NCAPH (mouse) PQGEEsHsGDGSTLE S191-p
D199-ca
EVEGHVAdGsAtEMG
0 1
NCAPH (human) EVEGHVAdGsAtEMG D199-ca
NCAPH (mouse) GEEsHsGDGSTLETE D193
S201-p
EGHVAdGsAtEMGtT
Upstream
0 14
Treatment
  • hesperadin
  • MG132
  • nocodazole
  • ZK-Thiazolidinone
NCAPH (human) EGHVAdGsAtEMGtT S201-p
NCAPH (mouse) EsHsGDGSTLETERT S195
T203-p
HVAdGsAtEMGtTKK
Upstream
0 2
Treatment
  • ZK-Thiazolidinone
NCAPH (human) HVAdGsAtEMGtTKK T203-p
NCAPH (mouse) HsGDGSTLETERTKK L197
T207-p
GsAtEMGtTKKAVKP
0 1
NCAPH (human) GsAtEMGtTKKAVKP T207-p
NCAPH (mouse) GSTLETERTKKPAKP R201
N228
RTIEQNINNLNVsEA
0 1
NCAPH (human) RTIEQNINNLNVsEA N228
NCAPH (mouse) KTIEQNLsNINVSEA S222-p
S233-p
NINNLNVsEADRkCE
Upstream
0 6
Treatment
  • ZK-Thiazolidinone
NCAPH (human) NINNLNVsEADRkCE S233-p
NCAPH (mouse) NLsNINVSEADGKCA S227
K238-ub
NVsEADRkCEIDPMF
0 2
NCAPH (human) NVsEADRkCEIDPMF K238-ub
NCAPH (mouse) NVSEADGKCAVDPMF K232
S335-p
DSETHNEsVSALVDK
0 1
NCAPH (human) DSETHNEsVSALVDK S335-p
NCAPH (mouse) DSETHNESVSALVDK S329
D366-ca
SDCGDFPdGSLGDDF
0 1
NCAPH (human) SDCGDFPdGSLGDDF D366-ca
NCAPH (mouse) DDEEDVPDGPLVEDF D359
K394-ub
HEEFRSWkEPCQVQs
0 1
NCAPH (human) HEEFRSWkEPCQVQs K394-ub
NCAPH (mouse) HEEFRSWKELCQVQS K387
S401-p
kEPCQVQsCQEEMIs
0 1
NCAPH (human) kEPCQVQsCQEEMIs S401-p
NCAPH (mouse) KELCQVQSNQEEVIS S394
S408-p
sCQEEMIsLGDGDIR
Upstream
0 11
Treatment
  • nocodazole
NCAPH (human) sCQEEMIsLGDGDIR S408-p
NCAPH (mouse) SNQEEVISLEDRDIQ S401
K424-ub
MCPLLSMkPGEysyF
0 1
NCAPH (human) MCPLLSMkPGEysyF K424-ub
NCAPH (mouse) MCSFLSMKPGEYSYF K417
Y428-p
LSMkPGEysyFsPRT
0 20
NCAPH (human) LSMkPGEysyFsPRT Y428-p
NCAPH (mouse) LSMKPGEYSYFsPRT Y421
S429-p
SMkPGEysyFsPRTM
0 15
NCAPH (human) SMkPGEysyFsPRTM S429-p
NCAPH (mouse) SMKPGEYSYFsPRTM S422
Y430-p
MkPGEysyFsPRTMS
0 14
NCAPH (human) MkPGEysyFsPRTMS Y430-p
NCAPH (mouse) MKPGEYSYFsPRTMK Y423
S432-p
PGEysyFsPRTMSMW
Upstream
0 31
Treatment
  • nocodazole
NCAPH (human) PGEysyFsPRTMSMW S432-p
NCAPH (mouse) PGEYSYFsPRTMKMW S425-p
K464
SQSENKKKSTKKDFE
0 1
NCAPH (human) SQSENKKKSTKKDFE K464
NCAPH (mouse) SCTEHKKkSAKKDFE K457-ac
K486
DFDVYFRKTkAATIL
0 1
NCAPH (human) DFDVYFRKTkAATIL K486
NCAPH (mouse) DFDAYFQkTKAATIL K479-ac
K488-ub
DVYFRKTkAATILTk
0 6
NCAPH (human) DVYFRKTkAATILTk K488-ub
NCAPH (mouse) DAYFQkTKAATILTK K481
K495-ub
kAATILTksTLENQN
0 3
NCAPH (human) kAATILTksTLENQN K495-ub
NCAPH (mouse) KAATILTKSTLENQN K488
S496-p
AATILTksTLENQNW
0 2
NCAPH (human) AATILTksTLENQNW S496-p
NCAPH (mouse) AATILTKSTLENQNW S489
Y514-p
TLPTDFNyNVDTLVQ
0 1
NCAPH (human) TLPTDFNyNVDTLVQ Y514-p
NCAPH (mouse) TLPTDFHYETDNLIQ Y507
L530
HLKPGTRLLkMAQGH
0 1
NCAPH (human) HLKPGTRLLkMAQGH L530
NCAPH (mouse) HLKPGKRsLKMDQDQ S523-p
K532-ub
KPGTRLLkMAQGHRV
0 2
NCAPH (human) KPGTRLLkMAQGHRV K532-ub
NCAPH (mouse) KPGKRsLKMDQDQKA K525
S570-p
PGLQAADsDDEDLDD
Upstream
Downstream
1 3
Effects on Modified Protein
  • phosphorylation
Effects on Biological Processes:
  • chromatin organization, altered
Kinase, in vitro:
  • CK2A1 (human)
NCAPH (human) PGLQAADsDDEDLDD S570-p
NCAPH (mouse) PGLQAADSDYEEADD S563
S589-p
PVGNSDLsPYPCHPP
0 3
NCAPH (human) PVGNSDLsPYPCHPP S589-p
NCAPH (mouse) PVGTLDLESDPKTTQ E582
T598-p
YPCHPPKtAQQNGDt
0 3
NCAPH (human) YPCHPPKtAQQNGDt T598-p
NCAPH (mouse) DLESDPKTTQENGHI T587
T605-p
tAQQNGDtPEAQGLD
Upstream
0 11
Treatment
  • AZD1152
  • BI2536
  • ZM447439
NCAPH (human) tAQQNGDtPEAQGLD T605-p
NCAPH (mouse) TQENGHIsPENQGVD S595-p
T614-p
EAQGLDItTyGESNL
0 2
NCAPH (human) EAQGLDItTyGESNL T614-p
NCAPH (mouse) ENQGVDITTYQELNL T604
Y616-p
QGLDItTyGESNLVA
0 2
NCAPH (human) QGLDItTyGESNLVA Y616-p
NCAPH (mouse) QGVDITTYQELNLVA Y606
K630-ub
AEPQKVNkIEIHyAk
0 1
NCAPH (human) AEPQKVNkIEIHyAk K630-ub
NCAPH (mouse) AEPQKVNKIEIHYAK K620
Y635-p
VNkIEIHyAkTAKKM
0 54
NCAPH (human) VNkIEIHyAkTAKKM Y635-p
NCAPH (mouse) VNKIEIHYAKTAKKM Y625
K637-ac
kIEIHyAkTAKKMDM
0 2
NCAPH (human) kIEIHyAkTAKKMDM K637-ac
NCAPH (mouse) KIEIHYAKTAKKMDM K627
K637-ub
kIEIHyAkTAKKMDM
0 1
NCAPH (human) kIEIHyAkTAKKMDM K637-ub
NCAPH (mouse) KIEIHYAKTAKKMDM K627
S653-p
KLKQSMWsLLTALSG
0 1
NCAPH (human) KLKQSMWsLLTALSG S653-p
NCAPH (mouse) KLKQSMWSLLTKFSR S643
K661
LLTALSGKEADAEAN
0 1
NCAPH (human) LLTALSGKEADAEAN K661
NCAPH (mouse) LLTKFSRkEADtEAN K651-ac
K661-ub
LLTALSGkEADAEAN
0 1
NCAPH (human) LLTALSGkEADAEAN K661-ub
NCAPH (mouse) LLTKFSRKEADtEAN K651
A665
LSGkEADAEANHREA
0 2
NCAPH (human) LSGkEADAEANHREA A665
NCAPH (mouse) FSRkEADtEANHTEs T655-p
A672
AEANHREAGkEAALA
0 1
NCAPH (human) AEANHREAGkEAALA A672
NCAPH (mouse) tEANHTEsGQEGAPE S662-p
K674-ac
ANHREAGkEAALAEV
0 1
NCAPH (human) ANHREAGkEAALAEV K674-ac
NCAPH (mouse) ANHTEsGQEGAPEEV Q664
K674-ub
ANHREAGkEAALAEV
0 3
NCAPH (human) ANHREAGkEAALAEV K674-ub
NCAPH (mouse) ANHTEsGQEGAPEEV Q664
K685
LAEVADEKMLSGLTk
0 1
NCAPH (human) LAEVADEKMLSGLTk K685
NCAPH (mouse) PEEVADEkKLSGLTK K675-ac
K685-ub
LAEVADEkMLSGLTk
0 2
NCAPH (human) LAEVADEkMLSGLTk K685-ub
NCAPH (mouse) PEEVADEKKLSGLTK K675
K692-ac
kMLSGLTkDLQRSLP
0 1
NCAPH (human) kMLSGLTkDLQRSLP K692-ac
NCAPH (mouse) kKLSGLTKDLQTRLP K682
K692-ub
kMLSGLTkDLQRSLP
0 2
NCAPH (human) kMLSGLTkDLQRSLP K692-ub
NCAPH (mouse) kKLSGLTKDLQTRLP K682
K725-ub
LANEKNLkLEGTEDL
0 3
NCAPH (human) LANEKNLkLEGTEDL K725-ub
NCAPH (mouse) LANEKNLKLEGTEDL K715
K725-sm
LANEKNLkLEGTEDL
0 2
NCAPH (human) LANEKNLkLEGTEDL K725-sm
NCAPH (mouse) LANEKNLKLEGTEDL K715
S733-p
LEGTEDLsDVLVRQG
0 1
NCAPH (human) LEGTEDLsDVLVRQG S733-p
NCAPH (mouse) LEGTEDLSDVLVMQG S723